Apatinib Mesylate Tablets
Sponsors
The First Affiliated Hospital of Zhengzhou University, Tianjin Medical University Cancer Institute and Hospital, Jiangsu HengRui Medicine Co., Ltd., Peking University Third Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Conditions
ApatinibBiomarkerChildhood RhabdomyosarcomaColorectal NeoplasmsDigestive System NeoplasmsGastric CancerGastrointestinal NeoplasmsHCC - Hepatocellular Carcinoma
Phase 1
A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure
NCT02772029
Start: 2016-05-31End: 2017-09-30Target: 30Updated: 2016-05-13
Effect of Itraconazole on the Pharmacokinetics of Apatinib
CompletedNCT02836171
Start: 2016-07-31End: 2017-02-28Updated: 2017-02-27
Effect of Rifampicin on the Pharmacokinetics of Apatinib
CompletedNCT02836821
Start: 2016-05-31End: 2017-02-28Updated: 2017-02-27
Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
NCT03050411
Start: 2016-05-31End: 2019-10-31Target: 30Updated: 2017-02-10
Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in Children
NCT03868852
Start: 2019-01-01End: 2020-04-01Target: 48Updated: 2019-03-11
Phase 2
A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers
NCT03096184
Start: 2016-12-23End: 2019-05-01Target: 38Updated: 2018-10-09
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
NCT03219593
Start: 2017-09-07End: 2020-02-29Target: 30Updated: 2017-09-11
A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
CompletedNCT03267121
Start: 2017-10-01End: 2020-11-01Updated: 2023-10-17
Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)
NCT03271255
Start: 2018-05-23End: 2022-12-31Target: 80Updated: 2019-01-23
Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer
Not yet recruitingNCT06759090
Start: 2025-01-15End: 2028-06-15Target: 43Updated: 2025-01-06
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
Not yet recruitingNCT07357532
Start: 2026-01-31End: 2028-10-30Target: 44Updated: 2026-01-22
A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
Not yet recruitingNCT07682272
Start: 2026-07-01End: 2029-07-01Target: 120Updated: 2026-07-02
Phase 3
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
NCT04714190
Start: 2021-03-24End: 2025-06-30Target: 351Updated: 2023-12-21
Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
Not yet recruitingNCT06188455
Start: 2024-12-01End: 2026-12-01Target: 37Updated: 2024-01-03
Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Not yet recruitingNCT07314203
Start: 2026-12-25End: 2028-08-25Target: 118Updated: 2026-01-02
Phase 4
Unknown Phase
Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)
SuspendedNCT03743428
Start: 2020-10-22End: 2026-12-31Target: 40Updated: 2023-06-29
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
RecruitingNCT06480864
Start: 2024-08-09End: 2026-08-31Target: 38Updated: 2025-01-06
A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
Not yet recruitingNCT07618546
Start: 2026-05-25End: 2028-03-31Target: 208Updated: 2026-06-01